What does the complete blood count look like in a newly diagnosed older adult with multiple myeloma who may be eligible for transplant?

Complete Blood Count in Newly Diagnosed Multiple Myeloma (Transplant-Eligible Older Adults)

In a newly diagnosed older adult with multiple myeloma who may be eligible for transplant, the CBC typically shows normocytic normochromic anemia (hemoglobin <10 g/dL or ≥2 g/dL below normal), often with normal or elevated platelet counts initially, though thrombocytopenia may be present in advanced disease.

Expected CBC Findings

Anemia

• Normocytic, normochromic anemia is the hallmark finding 1
• Hemoglobin typically <10 g/dL or at least 2 g/dL below the lower limit of normal 1
• This anemia is one of the CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) used to diagnose symptomatic multiple myeloma requiring treatment 1
• The anemia results from bone marrow infiltration by clonal plasma cells and cytokine-mediated suppression of erythropoiesis

White Blood Cell Parameters

• Total white blood cell count is often normal or slightly decreased
• Absolute neutrophil count (ANC) may be normal or reduced depending on disease burden
• Absolute lymphocyte count can be variable
• Absolute monocyte count (AMC) has prognostic significance - lower counts at baseline predict better outcomes after transplant 2

Platelet Count

• Platelets are frequently normal at diagnosis in early-stage disease
• Thrombocytopenia (platelets <100,000-150,000/μL) may occur with:
  • Advanced bone marrow infiltration (>50% plasma cells)
  • More aggressive disease
  • Higher disease stage

Prognostic Inflammatory Markers from CBC

Recent evidence shows that inflammation-related indices derived from the CBC have prognostic value 2:

• Neutrophil-to-lymphocyte ratio (NLR): Elevated ratios indicate worse prognosis
• Lymphocyte-to-monocyte ratio (LMR): Higher ratios predict better outcomes
• Systemic inflammation response index (SIRI): Lower values (<1.56 pre-transplant) predict superior progression-free survival 2

Clinical Context for Transplant Eligibility

Key Diagnostic Requirements

The CBC must be interpreted alongside other diagnostic criteria 1:

• ≥10% clonal plasma cells on bone marrow examination
• Evidence of end-organ damage (CRAB criteria)
• Complete blood count is mandatory for staging 3

Transplant Eligibility Considerations

Chronologic age and CBC abnormalities alone should not determine transplant eligibility 4. The assessment should include:

• Performance status (ECOG 0-2 preferred)
• Comorbidities
• Organ function beyond just CBC parameters
• Disease characteristics (cytogenetics, ISS stage)

Patients with significant cytopenias at presentation can improve with induction therapy and become transplant-eligible, so early referral to a transplant center is essential 4.

Common Pitfalls to Avoid

1. Don't exclude transplant based solely on severe anemia or cytopenias at diagnosis - these often improve dramatically with induction therapy 4

2. Don't overlook the prognostic value of inflammatory indices - calculate NLR, LMR, and SIRI from the baseline CBC as these predict post-transplant outcomes 2

3. Don't assume normal CBC excludes myeloma - some patients, particularly those with smoldering myeloma or early-stage disease, may have relatively preserved blood counts 1

4. Monitor for worsening cytopenias during induction - grade ≥3 lymphopenia (25-45%), neutropenia (25-30%), and thrombocytopenia occur commonly with modern triplet/quadruplet regimens 5